WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced its participation in the following upcoming conferences:
BMO Capital Markets – Boston Biotech Corporate Access Day on Tuesday, July 29th at the Boston Harbor Hotel in Boston, Massachusetts 2014 InvestMNt conference sponsored by CFA Society of Minnesota on August 6th at 10:00 am ET (9:00am CT) at the University of St. Thomas in Minneapolis, Minnesota. This presentation will be webcast live by MeetMax and can be accessed by registering at www.investMNt.org. National Institutes of Health and Food and Drug Administration joint-sponsored workshop – “The Development of New Antibacterial Products: Charting the Course for the Future,” on Wednesday, July 30th at the Bethesda North Marriott Hotel and Conference Center, in Bethesda Maryland. Joyce Sutcliffe, Tetraphase Senior Vice-President, Biology, will participate in a panel discussion titled, “Streamlined Antibacterial Drug Development Pathways Targeting Unmet Need.”
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). Under this program, two Phase 3 clinical trials are ongoing: IGNITE 1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE 2 for complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability. Please visit www.tphase.com for more company information.
Investors:Tetraphase PharmaceuticalsDavid Lubner, email@example.comArgot PartnersSusan Kim, firstname.lastname@example.orgMedia:Sam Brown Inc.Mike Beyer, email@example.com
Source: Tetraphase Pharmaceuticals, Inc.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer